RIFAPENTINE - Generic Drug Details

What are the generic sources for rifapentine and what is the scope of freedom to operate?

Rifapentine is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for RIFAPENTINE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	45
Clinical Trials:	67
What excipients (inactive ingredients) are in RIFAPENTINE?	RIFAPENTINE excipients list
DailyMed Link:	RIFAPENTINE at DailyMed

Recent Clinical Trials for RIFAPENTINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	PHASE1
National Institute of Allergy and Infectious Diseases (NIAID)	PHASE1
National Institute of Mental Health (NIMH)	PHASE1

See all RIFAPENTINE clinical trials

Pharmacology for RIFAPENTINE

Drug Class

Rifamycin Antimycobacterial

Anatomical Therapeutic Chemical (ATC) Classes for RIFAPENTINE

J04AB	Antibiotics
J04A	DRUGS FOR TREATMENT OF TUBERCULOSIS
J04	ANTIMYCOBACTERIALS
J	Antiinfectives for systemic use

US Patents and Regulatory Information for RIFAPENTINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	PRIFTIN	rifapentine	TABLET;ORAL	021024-001	Jun 22, 1998		RX	Yes	Yes

RIFAPENTINE Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for Rifapentine?

The global rifapentine market is driven primarily by its application in tuberculosis (TB) treatment, specifically for active TB and latent TB infection (LTBI). The drug's relevance is increasing due to the ongoing global TB burden, especially in regions with high disease prevalence, such as Southeast Asia, Africa, and parts of Eastern Europe.

Key Drivers:

• TB Epidemiology: The World Health Organization (WHO) reports approximately 10 million new TB cases annually, with drug-resistant strains complicating treatment. Rifapentine’s favorable pharmacokinetics makes it suitable for longer regimens which improve adherence.

• Regulatory Approvals: The drug's approval for latent TB infection in the U.S. (FDA, 2014) and broader indication expansions in Asia and Europe underpin market growth. The CDC recommends rifapentine-based regimens, enhancing adoption.

• R&D Intensification: Pharmaceutical firms invest in combination therapies featuring rifapentine, aiming to shorten treatment durations and improve compliance rates.

• Generic Competition: With patent expirations expected around 2024-2027, generic availability could lower prices and expand access, influencing market share distribution.

Market Challenges:

• Limited Awareness & Diagnosis: Insufficient TB screening and diagnostics in developing regions restrict the drug’s uptake.

• Pricing & Reimbursement: Cost remains a barrier in low-income settings, impacting adoption despite clinical advantages.

• Safety Profile: Few adverse effects are identified, but toxicity concerns, particularly hepatotoxicity, hinder some clinician confidence, delaying widespread implementation.

How Is the Financial Trajectory Shaping Up?

The rifapentine market is projected to expand at a compound annual growth rate (CAGR) of approximately 7-9% from 2023 through 2028[1].

Market Size and Forecast:

Year	Estimated Market Value (USD millions)	Notes
2023	150	Base year, considering existing demand, generics entering markets, and regulatory shifts.
2025	180 - 200	Increased uptake with broader approvals; expansion into new regions.
2028	210 - 230	Market maturation; consistent growth driven by ongoing TB control initiatives.

Revenue Segmentation:

• North America: Approximately 35-40%, given high TB awareness and regulatory approval for latent TB treatment.
• Europe: 15-20%, with expanding indications and reimbursement policies.
• Asia-Pacific: 25-30%, propelled by high TB prevalence and emerging markets.
• Rest of World: 10-15%, mostly driven by Latin America and Africa, where generic versions may influence volume more than price.

Key Companies and Market Share:

• Johnson & Johnson: Original patent holder (Trade name: Priftin), with licensing for generic manufacturing post-2024.
• Ongoing R&D: Several biotech firms exploring new formulations and combination therapies, aiming to extend patent life or develop next-generation drugs.

What Are the Future Opportunities and Risks?

Opportunities:

• Novel formulations: Fixed-dose combinations (FDCs), once-daily regimens, and reduced dosing schedules can improve adherence.
• Expanded indications: Use in multidrug-resistant TB (MDR-TB) and pediatric populations remains under-explored.
• Global health initiatives: Increased funding from WHO and Gavi can accelerate access and adoption.

Risks:

• Patent expiry: Entry of generics around 2024 could disrupt pricing structures.
• Regulatory delays: Additional approvals needed for new indications or in certain markets may slow sales.
• Market saturation: As TB control programs plateau or improve, the incremental growth may decline.

Key Takeaways

• The rifapentine market is expanding driven by the global TB burden and drug’s clinical advantages.
• Revenue growth is projected at 7-9% CAGR from 2023 to 2028, with regional disparities in market share.
• Patent expiry around 2024 introduces both competition and price pressure.
• New formulations and expanded indications present lucrative avenues.
• Funding from international health initiatives can boost market penetration in low-income regions.

FAQs

1. When will generic rifapentine become available?
Expected around 2024-2027, following patent expiration.

2. Which regions offer the highest growth potential?
Asia-Pacific, due to high TB prevalence, and developing markets in Africa and Latin America.

3. What are the primary barriers to market growth?
Limited TB screening, pricing challenges, and regulatory approval delays.

4. Are there any new formulations of rifapentine in development?
Yes, research is ongoing for FDCs, reduced dosing schedules, and pediatric formulations.

5. How might TB control initiatives influence market dynamics?
Increased funding and policy support can accelerate uptake and lead to market expansion.

---

References:

[1] MarketWatch, "Global Rifapentine Market Size, Share and Growth Forecast 2023-2028," 2023.